In this study we report the isolation and purification of the capsular polysaccharide elaborated by Staphylococcus aureus SAl mucoid. The capsule was isolated from bacterial extracts and culture supernatants by a series of ethanol precipitations and enzyme digestions, followed by ion-exchange chromatography. Teichoic acid contamination was eliminated by oxidation with sodium metaperiodate, and the final product eluted in the void volume of a Sephacryl S-300 column. The purified capsular polysaccharide was analyzed by gas-liquid chromatography-mass spectroscopy, 13C and 'H nuclear magnetic resonance, amino acid analysis, immunelectrophoresis, and numerous biochemical assays. The major constituents of the capsule were 2-acetamido-2-deoxy-a-galacturonic acid (4-0 linked), 2-acetamido-2-deoxy-a-fucose (3-0 linked), and taurine. The polysaccharide also contained O-acetyl groups which were removed by mild alkaline hydrolysis. Serologically and biochemically, the capsule from strain SAl mucoid appeared very similar to that produced by strain M. Purified capsular polysaccharide was immunogenic in both rabbits and mice. The optimal immunizing dose in mice was 0.1 ,ig of purified capsular polysaccharide administered intraperitoneally. SAl mucoid resisted opsonophagocytic killing by human leukocytes and complement. However, antibodies raised to the purified capsular polysaccharide neutralized the antiphagocytic effect of the capsule.
Bacterial capsules are important virulence determinants for organisms that cause invasive disease. Capsular polysaccharides from a number of bacterial species have been studied extensively for their role in pathogenesis and possible use as vaccines (6, 19, 34) . The enhanced virulence of encapsulated bacteria is generally attributed to their resistance to phagocytosis, a property that the capsule imparts to the bacterium (16, 18, 27) . Capsules may physically mask C3b deposited on the cell wall that, in the absence of a capsule, allows for phagocyte attachment, engulfrnent, and killing of the bacterium (34, 35) . This antiphagocytic effect of the bacterial capsule can usually be neutralized by specific antibodies (16, 18, 27, 34) .
Previous studies have shown that encapsulated strains of Staphylococcus aureus are more virulent for mice than strains lacking capsules are (20, 33, 38) . Furthermore, the immunity induced by S. aureus capsular antigens protects mice against experimental staphylococcal lethality. Mice immuniZed with encapsulated S. aureus (8, 9) or culture supernatants from these strains (10) became resistant to a lethal intraperitoneal dose of the homologous organism. Polysaccharide antigens extracted from these encapsulated strains also protected mice against a lethal inoculum of S. aureus (9, 20, 25) . Protection could be passively transferred to naive animals with immune serum (11) . Nonimmune mice or mice immunized with killed, unencapsulated S. aureus were not protected against lethality induced by capsuleproducing strains (8) . Capsular polysaccharides have been described and partially characterized from at least 16 S. aureus strains (34) . The three S. aureus isolates whose capsules have been best characterized biologically and biochemically are strains M, T, and Smith diffuse (34) . Strain M produces a capsule composed of 2-acetamido-2-deoxy-D-galacturonic acid, 2-acetamido-2-deoxy-D-fucose, and taurine (22, 26) . Capsular * Corresponding author. material from strain T contains 2-acetamido-2-deoxy-Dmannuronic acid and 2-acetamido-2-deoxy-D-fucose (36) , whereas the Smith diffuse capsule consists of 2-acetamido-2-deoxy-D-glucuronic acid and 2-acetamido-2-deoxy-Lalanyl glucuronic acid (15) . However, Karakawa and Vann (18) 8 capsule from strain Becker and found O-acetyl groups, 2-acetamido-2-deoxy-D-fucose and an aminouronic acid similar to 2-acetamido-2-deoxygalacturonic acid.
The purpose of our study was to purify the capsular polysaccharide from a mucoid variant strain of S. aureus derived spontaneously from a toxic shock isolate. We biochemically characterized the polysaccharide and determined its immunogenicity in rabbits and mice. Antibodies raised to the purified capsular polysaccharide (PCP) neutralized the antiphagocytic effect of the capsule in a complementdependent opsonophagocytic killing assay.
MATERIALS AND METHODS
Bacteria. Strain SAl, a toxic shock isolate of S. aureus, and strain SAl mucoid, a highly encapsulated, spontaneous mutant derived from strain SA1, have been described previously (21 equipped with a pH titrator set to maintain pH 7.2. The culture was aerated with a rotating sparger and agitated at 250 to 300 rpm. The culture medium optimal for capsule production and recovery was Columbia broth (Difco) modified by the addition of 0. 1% D-glucose, 1% yeast extract, and 0.5% NaCI (18) . An ultrafiltrate of this medium was prepared by passing the broth through a Pellicon cassette system (Millipore Corp., Bedford, Mass.) with membranes with a cutoff of 10,000 daltons. Exclusion of high-molecular-weight components from the growth medium facilitated the isolation of high-molecular-weight, soluble capsular polysaccharides excreted into the medium during bacterial growth. At the end of the growth period, the broth was checked for purity by Gram stain and culture. The organisms were harvested in a Sharples Super-Centrifuge (Pennwalt Corp., Warminster, Pa.). Both the bacterial pellet and the culture supernatant were used for antigen purification.
The bacteria (200 to 400 g [wet weight]) were suspended in approximately 500 ml of 0.05 M Tris buffer-1 mM MgCl2-1 mM CaCl2, pH 7.3, and subjected to mechanical agitation with glass beads in a Vibrogen (Edmund Buhler Co., Tubingen, Federal Republic of Germany) for 10 to 15 min at 4°C. The glass beads were removed by filtration, and the following enzymes were added to the bacterial slurry: 10 mg of lysostaphin (Sigma Chemical Co., St. Louis, Mo.), 10 mg of DNase (Worthington Diagnostics, Freehold, N.J.), and 25 mg of RNase (Worthington). After overnight incubation at 37°C, the enzymes were added again the following morning. Six hours later, 100 mg of pronase (Calbiochem, San Diego, Calif.) was added to the bacterial suspension, and the mixture was incubated at 37°C overnight. The bacteria were removed by centrifugation at 10,000 x g and discarded. The supernatant was filtered through a 0.45-,um-pore-size membrane (Millipore) and precipitated with 30% ethanol (vol/vol) at 4°C overnight to partially remove nucleic acids and proteins. The supernatant was brought to a concentration of 80% ethanol (vol/vol) and kept at 4°C overnight. The precipitate was dissolved in deionized water, dialyzed extensively at 4°C, and lyophilized. The 20-liter culture supernatant was sequentially filtered through 1.2-, 0.8-, and 0.45-pm-pore-size membranes and concentrated to approximately 300 ml in a Pellicon cassette system (Millipore) with a membrane with a cutoff of 10,000 daltons. Nucleic acids and proteins were partially removed by fractionation with 30% ethanol (vol/vol) at 4°C overnight. After centrifugation at 6,000 x g for 30 min, the supernatant was precipitated in 80% (vol/vol) ethanol at 4°C overnight. The white, flocculent precipitate was suspended in approximately 100 ml of 0.05 M Tris buffer-1 mM MgCl2-1 mM CaCl2, pH 7.3. The solution was digested overnight at 37°C with 2 mg of DNase, 10 mg of RNase, 2 mg of lysostaphin, and 10 mg of lysozyme (Sigma). The enzymes were added again the following morning, follpwed by overnight digestion at 37°C with 10 mg of pronase. The sample was dialyzed for 48 h at 4°C against deionized water and lyophilized. The crude capsular antigens (bacterial extract and culture supernatant) were processed in parallel through the rest of the purification scheme.
Crude capsular material (ca. 500 mg) was passed over a column (2.6 by 30 cm) of DEAE-Sephacel (Pharmacia Fine Chemicals, Piscataway, N.J.) equilibrated with 0.05 M Tris buffer, pH 7.3, containing 0.005% chlorhexidine. The column was washed with several column bed volumes of the starting buffer, and the unbound material was discarded. The capsular antigen was eluted by washing the column in Tris buffer with a linear gradient of 0 to 0.5 M NaCl. The column eluate was monitored for A206 of UV light (Uvicord S; LKB Instruments, Inc., Rockville, Md.), and conductivity (in millisiemens) was measured on every tenth fraction. Optically active fractions were pooled, dialyzed, and lyophilized. The pooled material was analyzed for serologic activity by immunodiffusion with antiserum raised in rabbits to Formalin-killed SAl mucoid (21) . Serologically active material eluted from the anion-exchange column with 0.32 M NaCl. To resolve any cationic contaminants, the capsular antigen (-500 mg) was chromatographed over a column (2.6 by 30 cm) of CM-Sepharose (Pharmacia), equilibrated with 0.01 M citrate buffer, pH 5.5, containing 0.01% merthiolate. The column eluate was monitored at 206 nm, as described above. Serologically active fractions not retained on this column were pooled, dialyzed, and lyophilized.
After ion-exchange chromatography, the crude capsular material showed a double precipitin line in immunodiffusion assays with serum raised to Formalin-killed SAl mucoid. To remove contaminating teichoic acid, which copurifies with the capsular polysaccharide, the samples were treated with 0.05 M NaIO4 at room temperature in the dark. The reaction was followed spectrophotometrically by measuring a progressive drop in A225 of the samples, reflecting the consumption of periodate. The reaction was complete after 72 h, at which time the sample was dialyzed and lyophilized. After this treatment, the sample produced a single precipitin line by immunodiffusion against SAl mucoid antiserum.
The final step in the purification scheme was chromatography on a column (1.6 by 90 cm) of Sephacryl S-300 (Pharmacia) equilibrated in 0.1 M ammonium bicarbonate buffer, pH 7.3, at a flow rate of 24 Biochemical analysis of the S. aureus capsular polysaccharide. The protein content of the PCP was determined by the methods of Lowry et al. (24) and Bradford (4) . Total hexoses and hexosamines were quantitated as described by Loewus (23) (32) . Sugar and methylation analyses were performed on the carboxyl-reduced polysaccharide. Samples were hydrolyzed with 4 N HCl for 2 h at 100°C. After evaporation of the HCI until neutrality (by coevaporation with water), the hexosamines were detected in the hydrolysates by identification of their deamination products (7) . Alditol acetate derivatives were prepared (29) (21) . The titer of immune rabbit serum was expressed as the highest dilution of serum giving an optical density reading at least 2 standard deviations greater than that of preimmune serum diluted 1:100. Coating antigen for the ELISA was PCP (2 ,ug/ml) coupled to poly-L-lysine by the cyanuric chloride method (13) .
Groups of 4 to 15 mice were immunized intraperitoneally on days 0, 5, and 10 with either phosphate-buffered saline, 108 Formalin-killed S. aureus, or PCP. For some experiments, we immunized mice with equivalent concentrations of PCP and mBSA. The animals were bled by tail vein puncture before each immunization and 5 days after the last immunizing dose. Sera were diluted 1:100 in phosphatebuffered saline containing 0.05% Tween 20 and tested for antibodies to PCP by ELISA (21) . Antibody levels were expressed as ELISA indices, calculated by dividing the absorbance reading of the test serum by the absorbance reading of a pool of high-titered immune mouse serum (raised to killed SAl mucoid).
Opsonophagocytic killing assay. Ten milliliters of heparinized human blood was obtained from healthy adult volunteers by venipuncture. The blood was mixed with 3 ml of 6% dextran in 0.15 M saline and allowed to sediment for 1 h at 37°C. The leukocytes in the leukocyte-rich plasma were pelleted by centrifugation and washed in 10 ml of Eagle minimal essential medium (MEM; GIBCO Laboratories, Lawrence, Mass.). Erythrocytes were lysed for 5 min in 0.84% ammonium chloride. After two washes in MEM, the leukocytes were enumerated by hemacytometer counts. Viability was determined by the trypan blue exclusion method. Cell concentrations were adjusted to 4.0 x 107 cells per ml of MEM.
Immune mouse sera raised to Formalin-killed bacteria or PCP were obtained as described above and heat activated at 56°C for 30 min. For certain experiments, immune serum was adsorbed overnight at 4°C with -109 S. aureus pretreated for 2 h at 37°C with trypsin (1 mg/ml) to remove protein A. Guinea pig complement (Pel-Freez Biologicals, Rogers, Ark.) was reconstituted and used as recommended by the manufacturer. Human antiserum (gamma globulin fraction) to S. aureus ribitol teichoic acid was obtained from Calbiochem.
Strain SAl mucoid was grown in 10 ml of modified Columbia broth as described above, centrifuged at 5,000 x g, and suspended in MEM to an A650 of 0.4, representing 2 x 108 CFU/ml. The bacteria were diluted to 2 x 107 CFU/ml of MEM before use.
The killing assay was performed in Eppendorf tubes to which 0.1-ml volumes containing the following were added: 4 x 106 leukocytes, complement, 12.5% mouse serum, and 2 x 106 CFU of S. aureus. Control tubes contained S. aureus and each of the other three components of the assay, alone and in combination. The tubes were rotated end-over-end for 2 h at 37°C. Bacterial-viability estimations (in CFU per milliliter) were done as a measure of phagocytosis, since other investigators have determined that staphylococci are readily killed after engulfment by polymorphonuclear leukocytes (1). At 0, 60, and 120 min, 100-tJ samples of the diluted cell suspensions were plated in duplicate on tryptic soy agar plates. The results were expressed as the percentage of the bacteria killed, calculated by the following formula: {1 -[(CFU/ml at 1 or 2 h)/(CFU/ml at 0 h)]} x 100. Each experiment was performed at least three times. RESULTS Biochemical characterization of S. aureus PCP. Using the methods described above, we polysaccharide from S. aureus SAl mucoid. From 20-liter cultures, we recovered 200 to 300 mg of PCP. Apparently, most of the high-molecular-weight polysaccharide remained cell associated, since -80% of the PCP was recovered from cellular extracts of SAl mucoid. Highly purified preparations derived from culture supernatants or bacterial cell extracts were biochemically identical. Table 1 shows a representative chemical analysis performed on PCP prepared from bacterial extracts of strain SAl mucoid. The protein content of PCP was 0.3% with alanine and glycine, constituting 52 and 9.5% of the total amino acid content, respectively. The presence of these amino acids is consistent with a low level of cell wall contamination in our PCP preparation. The fatty acid content of PCP was 1.2% and the individual fatty acids resolved by GLC were identified as tetradecanoic (54%), hexadecanoic (17%), octadecanoic (24%), and eicosanoic (5%) acids. GLC-MS analysis of PCP after reduction of the carboxyl groups with carbodiimide and sodium borodeuteride indicated that it contained 2-acetamido-2-deoxy-galacturonic acid (GalNAcU) and 2-acetamido-2-deoxy-fucose (FucNAc). This was established by identification of their deamination products (2,5-anhydro-talitol and 6-deoxy-2,5-anhydrotalitol, respectively) as alditol acetates with the first separation column. In addition, 2,5-anhydro-talitol was doubly deuterated at position 6, confirming the presence of the carboxylic function. PCP also contained minor peaks of 2-acetamido-glucose, glucose, and heptose, probably a result of cell wall contamination. However, no ribitol was detected.
A preliminary analysis of PCP by 13C NMR (Fig. 1) confirmed the presence of GalNAcU and FucNAc and revealed taurine substitutions similar to those described for strain M (26 3 .145 ppm integrating for one proton could be assigned to the methylene protons of a taurine residue. Because only one proton was observed, there was apparently only a single taurine present for every 9 to 12 sugar residues. In the upfield region of the spectrum, signals between 1.95 and 2. We were unable to accurately quantitate the amounts of GalNAcU and FucNAc in PCP because commercial standards for these sugars are not currently available. Furthermore, our sample yields were very low, presumably because of polymer degradation during the chemical manipulations necessary to prepare PCP for analysis. We detected only a low level of uronic acid (0.2%) in PCP by the carbazole method (Table 1) , since uronic acid sugars substituted with amino groups react poorly in this assay (3) .
For linkage analysis of the carboxyl-reduced polysaccharide, the samples were methylated, hydrolyzed, and analyzed by GLC-MS with the second separation column, as described in Materials and Methods. Detection of 3,6(methyl)2-GalNAc (doubly deuterated at position 6) and 4-methylFuc-N(methyl)Ac indicated (1->4)-linked GalNAcU and (1--3)-linked FucNAc, respectively. These data suggest that the structure of PCP prepared from SAl mucoid is very similar to that previously described by Murthy et al. (26) for strain M, except that the latter apparently lacks O-acetyl groups and contains a higher taurine content. The similarity between the capsular polysaccharides produced by these two strains was confirmed serologically as described below.
Serologic analysis of S. aureus PCP. Capsular polysaccharides purified from bacterial cell extracts or culture supernatants of SAl mucoid were serologically identical by double immunodiffusion analysis. PCP produced a single precipitin line by immunodiffusion against rabbit serum raised to Formalin-killed SAl mucoid (Fig. 2) ducing heterologous capsules, Smith diffuse (15) and NS58D (37) (Fig. 2) .
Immunogenicity of PCP. We injected rabbits and mice with PCP to evaluate its immunogenicity. Rabbits immunized with PCP and mBSA produced capsular antibodies after a series of immunizations over a 3-to 5-week period. Maximal titers of 1:800 were obtained by an indirect ELISA method (21) .
Groups of mice were immunized intraperitoneally every 5 days with doses of PCP ranging from 0.01 to 50 jig per mouse. Antibodies could be detected in diluted sera of immunized mice after two doses of PCP (Fig. 3) . The optimal immunizing dose of PCP was 0.1 ,ug per mouse. No enhancement of immunogenicity was apparent when mBSA was included as an adjuvant, and immunologic unresponsiveness was noted at PCP doses greater than 0.5 ,ug.
Opsonophagocytic killing assays. To determine if PCP antibodies promoted phagocytic killing of S. aureus, we measured their opsonic activity in an in vitro opsonophagocytic killing assay. (Table 2) , but a higher serum concentration (25%) was necessary to achieve >90% killing. In the absence of leukocytes, none of the sera tested caused a reduction in the number of CFU per milliliter. Furthermore, complement-mediated phagocytic killing of SAl mucoid was not observed with human antibodies to teichoic acid (data not shown.).
DISCUSSION
In this study we report the isolation and purification of the capsular polysaccharide elaborated by S. aureus SAl mucoid. Although we recovered PCP from culture supernatants, 80% of the high-molecular-weight polysaccharide was recovered from bacterial cells by mechanical agitation and enzymatic lysis. The capsule was isolated by a series of ethanol precipitations and enzyme digestions, followed by ion-exchange chromatography. Removal of teichoic acid was achieved by subjecting the polysaccharide preparation to oxidation with sodium metaperiodate. This process cleaved the teichoic acid into smaller fragments, which were then separated from the capsule by dialysis and molecular sieve chromatography. Capsular antigens recovered from bacterial extracts or culture supernatants of the organism were serologically and biochemically identical.
The major constituents of PCP were GalNAcU, FucNAc (both in the a configuration), and taurine. The polysaccharide was 0 acetylated, and the linkages were (1--4)Gal NAcU and (1-*3)FucNAc. A six-sugar repeating unit was estimated with taurine substitutions on every 9 to 12 sugar residues. We were unable to quantitate the percentage composition of PCP because of our poor yields after carboxyl reduction, hydrolysis, and derivatization of the polysaccharide. However, the purity of our samples was deduced by the absence of other constituents when PCP was analyzed by chemical assays, GLC-MS, and NMR. S. aureus M also produces a capsular polysaccharide composed of GaINAcU, FucNAc, and taurine (22, 26) . PCP prepared from strain SAl mucoid is apparently very similar to the strain M capsule, except that the latter has a greater taurine content (one every four GalNAcU residues) and lacks O-acetyl groups. Likewise, by immunodiffusion, PCP prepared from SAl mucoid formed a precipitin line of identity with strain M but not with two strains producing heterologous capsules (Fig. 2) . These findings suggest that strains M and SAl mucoid produce very similar capsule types. The capsules elaborated by strains SAl mucoid and Becker (12) (type 8 capsule) were also biochemically similar, except that the type 8 capsule lacks taurine. The serologic relatedness of these strains has not been determined. Although Wilkinson et al. (35) reported that the presence of taurine in the strain M capsule was growth medium dependent, we could not detect taurine in our culture medium analyzed for its amino acid content (unpublished observation).
PCP prepared from strain SAl mucoid was immunogenic in both rabbits and mice. The highest antibody levels in mice were achieved at a dose of 0.1 ,ug of PCP, and mice given doses greater than 0.5 ,ug demonstrated immune unresponsiveness (Fig. 3) . Similar doses of capsular material prepared from the Smith diffuse strain of S. aureus were used by We demonstrated that mouse antibodies raised to PCP were opsonic for SAl mucoid by an in vitro opsonophagocytic assay. Like strain M (27, 35) , SAl mucoid required both capsular antibodies and complement for phagocytic killing. Opsonic antibodies raised to Formalin-killed SAl mucoid were not adsorbed with the nonmucoid parent strain SAl. Previously, we showed that strain SAl elaborated a microcapsule demonstrable by immunoelectron microscopy (21) . More recently, we have shown that SAl cells treated with trypsin to remove protein A have no capsule demonstrable by immunoelectron microscopy (J. C. Lee, C. A. Hopkins, N. E. Perez, and G. B. Pier, manuscript in preparation). This suggests that the previously observed microcapsule was an artifact caused by immunoglobulins in immune serum binding cell wall-associated protein A. This hypothesis is consistent with serologic data showing that capsular antibodies do not react with bacterial extracts of SAl parent (Fig. 2) . Furthermore, mice injected (20) or immunized (J. C. Lee, M. J. Betley, C. A. Hopkins, N. E. Perez, and G. B. Pier, J. Infect. Dis., in press) with strain SAl do not elicit a capsular antibody response.
In summary, we have isolated and purified the capsular polysaccharide from a highly encapsulated isolate of S. aureus. We used this polysaccharide to immunize mice and showed that antibodies raised to PCP enhanced phagocytic uptake and killing of strain SAl mucoid in an in vitro assay. Studies that will be reported elsewhere describe the protective effect of PCP antibodies in a mouse model of staphylococcal infection. 
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